MITOXANTRONE AND MITOMYCIN-C AS 2ND-LINE TREATMENT FOR ADVANCED BREAST-CANCER

被引：4

作者：

REPETTO, L

MIGLIETTA, L

GARDIN, G

NASO, C

GIUDICI, S

MERLINI, L

QUEIROLO, P

CAMPORA, E

PRONZATO, P

ROSSO, R

机构：

[1] Divisione di Oncologia Medica, Istituto Nazionaie per la Ricerca sul Cancro, Genova

来源：

ANNALS OF ONCOLOGY | 1992年 / 3卷 / 02期

关键词：

MITOXANTRONE; MITOMYCIN-C; 2ND-LINE TREATMENT; BREAST CANCER;

D O I：

10.1093/oxfordjournals.annonc.a058135

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Forty-three evaluable patients with advanced breast cancer were treated with a combination of mitoxantrone 10 mg/sqm and mitomycin C 10 mg/sqm every 3 weeks. Two patients (4%) achieved objective responses lasting 3 and 16 months. The median duration of survival after protocol entry was 6 months (range 1-22) and the median progression-free survival was 3.5 (range 1-20). Only mild toxicities were observed. We concluded that the mitoxantrone and mitomycin C combination has limited toxicity but low activity and only brief disease palliation in advanced breast cancer.

引用

页码：165 / 166

页数：2